-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Kadmon announced that the US FDA approved the company's Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD) patients over 12 years of age who have received two pre-systemic treatments
Hematopoietic stem cell transplantation is a common treatment for blood or bone marrow cancer
As a ROCK2 kinase inhibitor, belumosudil can reduce the phosphorylation of STAT3 and strengthen the phosphorylation of STAT5, thereby down-regulating over-activated T helper cells (Th17) and enhancing the function of regulatory T cells (Treg), thereby rebuilding immune balance
▲Illustration of the mechanism of action of Belumosudil (picture source: reference [2])
The FDA approval is based on the results of a random, open-label, multi-center pivotal clinical trial called ROCKstar
"Rezurock is a new treatment model for thousands of cGVHD patients
Reference materials:
[1] US FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD).
[2] Kadmon Corporate Presentation.